Clinical trial NCT00392886: Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
Official title: Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Brain and Central Nervous System Tumors
Keywords: untreated childhood medulloblastoma
untreated childhood supratentorial primitive neuroectodermal tumor
childhood infratentorial ependymoma
childhood supratentorial ependymoma
newly diagnosed childhood ependymoma
childhood high-grade cerebral astrocytoma
childhood oligodendroglioma
childhood atypical teratoid/rhabdoid tumor
childhood choroid plexus tumor
untreated childhood cerebellar astrocytoma
untreated childhood visual pathway and hypothalamic glioma
untreated childhood pineoblastoma
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2006-10-26
Enrollment: 120
Sex: ALL
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A bone marrow or peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed.

PURPOSE: This phase III trial is studying how well giving combination chemotherapy with or without etoposide followed by an autologous stem cell transplant works in treating young patients with previously untreated malignant brain tumors.

Detailed description: OBJECTIVES:

Primary

* Determine the 2-year event-free survival (EFS) and overall survival (OS) of pediatric patients with previously untreated nondisseminated medulloblastoma (\< 4 years of age), disseminated medulloblastoma (\< 10 years of age), or noncerebellar primitive neuroectodermal tumors (PNET) (disseminated or non-disseminated) treated with induction chemotherapy followed by consolidation with myeloablative chemotherapy and autologous hematopoietic stem cell rescue.
* Determine the toxicity of this regimen in these patients.
* Determine the mortality of patients treated with this regimen.

Secondary

* Determine the complete and partial response rates after completion of induction chemotherapy in these patients stratified according to pathology (medulloblastoma vs noncerebellar PNET vs high-grade gliomas vs atypical teratoid/rhabdoid tumors vs choroid plexus carcinomas and atypical papillomas vs ependymomas).
* Describe the EFS and OS of these patients stratified according to additional diagnoses (atypical teratoid/rhabdoid tumors vs choroid plexus carcinomas and atypical choroid plexus papillomas vs ependymomas vs high-grade gliomas).
* Describe the time to progression and patterns of relapse in these patients stratified by diagnosis and radiotherapy received (\< 6 years of age with evidence of no residual tumor pre-transplant and no post-transplant consolidation radiotherapy vs \< 6 years of age with residual tumor present pre-transplant treated with post-transplant consolidation radiotherapy vs \> 6 years of age treated with post-transplant consolidation radiotherapy).
* Determine the neuropsychometric function, endocrinologic function, and physical growth in these patients stratified according to radiotherapy received (none vs reduced-volume craniospinal radiotherapy vs focused local-field radiotherapy).

OUTLINE: This is a pilot study. Patients are stratified according to type of tumor (nonglial vs glial and diffuse pontine).

* Regimen C (patients with glial tumors):

  * Stem cell harvesting (bone marrow and/or peripheral blood): Patients undergo leukapheresis or bone marrow aspiration to collect bone marrow or peripheral blood stem cells prior to beginning induction chemotherapy or after the first course of induction chemotherapy.
  * Induction chemotherapy: Patients receive vincristine IV on days 1, 8, and 15 of courses 1-3, oral temozolomide once daily on days 1-5, and carboplatin IV over 4 hours on days 1 and 2. Patients also receive G-CSF SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Patients with unresectable bulky disease and corticosteroid dependence are removed from study. All other patients proceed to consolidation chemotherapy.

* Consolidation chemotherapy: Patients receive carboplatin IV over 4 hours on days -8 to -6 and thiotepa IV over 3 hours on days -5 to -3.
* Autologous bone marrow or peripheral blood stem cell transplantation: Patients undergo reinfusion of bone marrow or peripheral blood stem cells on day 0. Patients also receive G-CSF SC beginning on day 1 and continuing until blood counts recover.
* Radiotherapy: Beginning within 6 weeks after stem cell transplantation, patients \> 6 years of age at diagnosis undergo radiotherapy once daily 5 days a week for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients ≤ 6 years of age undergo radiotherapy if there is evidence of tumor remaining after completion of induction chemotherapy.

  * Regimen D2 (patients with nonglial tumors):
* Stem cell harvesting (bone marrow and/or peripheral blood): Patients undergo leukapheresis or bone marrow aspiration to collect bone marrow or peripheral blood stem cells prior to beginning induction chemotherapy or after the first course of induction chemotherapy.
* Induction chemotherapy:

  * Courses 1, 3, and 5 (28 days per course): Patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days 2 and 3, high-dose methotrexate IV over 4 hours on day 4, and filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until blood counts recover. Patients also receive vincristine IV on days 1, 8, and 15 of courses 1 and 3.
  * Courses 2 and 4 (28 days per course): Patients receive oral temozolomide once daily on days 1-5, oral etoposide once daily on days 1-10, cyclophosphamide IV over 1 hour on days 11 and 12, and G-CSF SC beginning on day 13 and continuing until blood counts recover. Patients also receive vincristine IV on days 1, 8, and 15 of course 2.

Patients with unresectable bulky disease and corticosteroid dependence are removed from study. All other patients proceed to consolidation chemotherapy.

* Consolidation chemotherapy: Patients receive carboplatin IV over 4 hours on days -8 to -6 and thiotepa IV over 3 hours and etoposide IV over 3 hours on days -5 to -3.
* Autologous bone marrow or peripheral blood stem cell transplantation: Patients undergo re-infusion of bone marrow or peripheral blood stem cells on day 0. Patients also receive G-CSF SC beginning on day 1 and continuing until blood counts recover.
* Radiotherapy:Patients undergo radiotherapy as in regimen C. Patients in both regimens undergo neuropsychological testing after induction chemotherapy but before consolidation chemotherapy and then at 18, 36, and 54 months after completion of study treatment. Neuropsychometric and neuroendocrine testing is performed before and after radiotherapy. Quality of life is also assessed periodically.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed malignant brain tumor, including any of the following:

  * Posterior fossa medulloblastoma/primitive neuroectodermal tumor (PNET)\*

    * All stages allowed
    * Must be \< 4 years of age at diagnosis unless there is evidence of postoperative residual tumor (\> 1.5 cm² tumor area) or evidence of neuraxis or extraneural dissemination (high-stage)
    * Medulloblastoma, cerebral neuroblastoma, and ependymoblastoma allowed

      * Low-stage (standard-risk) medulloblastoma not allowed in patients \> 4 years of age
  * Ependymoma\*

    * All stages and locations allowed
    * Cellular and anaplastic subtypes allowed (no myxopapillary ependymomas of the spinal cord)
    * Must be \< 36 months of age at diagnosis for posterior fossa tumor OR \< 72 months of age for supratentorial tumor
    * Evidence of neuraxis dissemination irrespective of primary site
    * No cellular (low-grade) supratentorial ependymomas at any age with complete resection of parenchymally based (i.e., not periventricular) supratentorial tumors
  * Brain stem tumor\*

    * All stages allowed irrespective of extent of resection
    * No unbiopsied diffuse intrinsic pontine tumor
    * Tumor pathologically confirmed to be either malignant glioma or PNET allowed
  * High-grade glioma\*\*
  * Primary atypical teratoid/rhabdoid tumor of the CNS\*
  * Choroid plexus carcinoma or atypical choroid plexus papilloma\*

    * All stages and locations allowed
  * Anaplastic astrocytoma\*\*
  * Glioblastoma multiforme\*\*
  * Anaplastic oligodendroglioma\*\*
  * Anaplastic ganglioglioma\*\*
  * Other anaplastic mixed gliomas\*\*
  * Small-cell glioblastoma\*\*
  * Giant-cell glioblastoma\*\*
  * Gliosarcoma\*\*
* The following diagnoses or subtypes are not allowed:

  * Choroid plexus papilloma
  * Pineocytoma
  * Low-grade mixed glioma
  * Primary CNS germ cell tumor
  * Primary CNS lymphoma
  * Solid leukemic lesions (i.e., chloromas, granulocytic sarcomas)
  * Pleomorphic xanthoastrocytoma, low grade
  * Desmoplastic ganglioglioma
  * Low-grade astrocytoma
* Previously untreated disease
* Has undergone definitive surgery within the past 42 days NOTE: \*Patients receive treatment according to regimen D2

NOTE: \*\*Patients receive treatment according to regimen C

PATIENT CHARACTERISTICS:

* Bilirubin \< 1.5 mg/dL
* ALT and AST \< 2.5 times upper limit of normal
* Creatinine clearance and/or glomerular filtration rate ≥ 60 mL/min

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior radiotherapy or chemotherapy
* Prior corticosteroids allowed
* No concurrent corticosteroids for antiemesis only
* No concurrent brachytherapy or electron radiotherapy
* No concurrent dairy products or grapefruit juice with temozolomide administration

Primary outcomes:
measure: Time to tumor progression, disease recurrence, or death of any cause
measure: Event-free survival at 2 years
measure: Toxicity
Secondary outcomes:
measure: Response to induction as assessed by one-time tumor measurements at baseline and after completion of induction chemotherapy
measure: Time to death
measure: Overall survival
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Phoenix Children's Hospital Outpatient Center
state: Arizona
city: Loma Linda
country: United States
facility: Loma Linda University Cancer Institute at Loma Linda University Medical Center
state: California
city: Long Beach
country: United States
facility: Jonathan Jaques Children's Cancer Center at Miller Children's Hospital
state: California
city: Los Angeles
country: United States
facility: Childrens Hospital Los Angeles
state: California
city: Los Angeles
country: United States
facility: Mattel Children's Hospital at UCLA
state: California
city: Oakland
country: United States
facility: Children's Hospital and Research Center Oakland
state: California
city: Orange
country: United States
facility: Children's Hospital of Orange County
state: California
city: Wilmington
country: United States
facility: Alfred I. duPont Hospital for Children
state: Delaware
city: Jacksonville
country: United States
facility: Nemours Children's Clinic
state: Florida
city: Chicago
country: United States
facility: Children's Memorial Hospital - Chicago
state: Illinois
city: Chicago
country: United States
facility: University of Chicago Comer Children's Hospital
state: Illinois
city: Indianapolis
country: United States
facility: Riley's Children Cancer Center at Riley Hospital for Children
state: Indiana
city: Louisville
country: United States
facility: Kosair Children's Hospital
state: Kentucky
city: Grand Rapids
country: United States
facility: Helen DeVos Children's Hospital at Spectrum Health
state: Michigan
city: Minneapolis
country: United States
facility: Masonic Cancer Center at University of Minnesota
state: Minnesota
city: Kansas City
country: United States
facility: Children's Mercy Hospital
state: Missouri
city: Hackensack
country: United States
facility: Tomorrows Children's Institute at Hackensack University Medical Center
state: New Jersey
city: Bronx
country: United States
facility: Albert Einstein Cancer Center at Albert Einstein College of Medicine
state: New York
city: New Hyde Park
country: United States
facility: Schneider Children's Hospital
state: New York
city: New York
country: United States
facility: NYU Cancer Institute at New York University Medical Center
state: New York
city: New York
country: United States
facility: Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
state: New York
city: Syracuse
country: United States
facility: SUNY Upstate Medical University Hospital
state: New York
city: Cleveland
country: United States
facility: Rainbow Babies and Children's Hospital
state: Ohio
city: Cleveland
country: United States
facility: Cleveland Clinic Taussig Cancer Center
state: Ohio
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
city: Toledo
country: United States
facility: Toledo Children's Hospital
state: Ohio
city: Toledo
country: United States
facility: St. Vincent Mercy Medical Center
state: Ohio
city: Hershey
country: United States
facility: Penn State Children's Hospital
state: Pennsylvania
city: Houston
country: United States
facility: M. D. Anderson Cancer Center at University of Texas
state: Texas
city: Perth
country: Australia
facility: Princess Margaret Hospital for Children
state: Western Australia
city: Vancouver
country: Canada
facility: Children's & Women's Hospital of British Columbia
state: British Columbia
city: Winnipeg
country: Canada
facility: CancerCare Manitoba
state: Manitoba
city: Toronto
country: Canada
facility: Hospital for Sick Children
state: Ontario
city: Christchurch
country: New Zealand
facility: Christchurch Hospital
city: Wellington
country: New Zealand
facility: Wellington Children's Hospital
city: Bern
country: Switzerland
facility: Swiss Pediatric Oncology Group Bern
city: Bern
country: Switzerland
facility: Universitaets Kinderklinik
Study officials:
affiliation: Children's Hospital Los Angeles
name: Jonathan L. Finlay, MB, ChB
role: STUDY_CHAIR
affiliation: Children's Hospital Los Angeles
name: Girish Dhall, MD
affiliation: Children's Hospital Los Angeles
name: Kelley Haley, RN, BSN
References: